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Background: Pulmonary arterial hypertension (PAH) remains a debilitating and life-threatening
disease despite improvements in hemodynamics, exercise capacity and survival with recent
therapeutic advances. Health-related quality of life (HRQOL) has, therefore, been proposed
as an important outcome for evaluating care. Relatively little, however, is known regarding
HRQOL or its determinants in PAH. The Minnesota Living with Heart Failure questionnaire
was recently adapted and validated for HRQOL measurement in PAH. We applied this
pulmonary hypertension-specific version (MLHF-PH) to a larger population of PAH patients.
Methods: Ninety-three consecutive outpatients with PAH completed the MLHF-PH. Scores were
assessed for correlations with demographics, symptoms, hemodynamics and treatments.
Results: Patients with PAH had significantly impaired HRQOL as assessed by the disease-
specific MLHF-PH. Each physical and emotional component, as well as total scores on the
MLHF-PH indicated severely depressed HRQOL. As compared to other diagnoses, PAH associ-
ated with scleroderma had the worst HRQOL. Patients with WHO functional Class II symptoms
reported better HRQOL than Class III patients. Fatigue, weakness and abdominal discomfort
were each associated with more severely depressed HRQOL, as was current epoprostenol
use. With the sole exception of the right atrial pressure, hemodynamic measurements did
not correlate with HRQOL scores. Simultaneous evaluation of HRQOL with a non-disease-
specific questionnaire (SF-36) revealed a similarly impaired status, although identified fewer
associations with patient-specific factors.243 4643.
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1432 M. Zlupko et al.Conclusion: Severely impaired HRQOL is present in this population of patients with PAH eval-
uated with a disease-specific questionnaire. The availability of a pulmonary hypertension-spe-
cific HRQOL questionnaire may enable further targeted investigations of factors that might
improve outcomes.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Pulmonary arterial hypertension (PAH) is a devastating and
progressive condition that frequently causes cor pulmonale
and premature death.1e3 Patients with PAH suffer from
breathlessness, decreased exercise capacity, peripheral
edema, lightheadedness and syncope. Currently available
treatments often cause side effects including worsened
edema, nausea and diarrhea, and may require invasive,
cumbersome and at times painful modes of administra-
tion.4,5 Further, while effective at improving hemodynam-
ics, exercise capacity and survival, none of these therapies
is curative and varying degrees of impairment remain.6,7
Not surprisingly, health-related quality of life (HRQOL) in
patients with PAH is significantly impaired.
HRQOL reflects the impact of health issues on one’s
satisfaction with life and ability to meet physical and
emotional needs. Physicians can use assessments of HRQOL
to better define and understand how an illness interferes
with a patient’s day-to-day living. Identifying disease-
specific factors that influence HRQOL may allow physicians
to select meaningful therapeutic interventions, improve
the quality and delivery of care, and optimize clinical
outcomes. Indeed, assessments of HRQOL are now
commonly used as clinical trial endpoints of many disease
states, particularly chronic conditions where the quality of
a patient’s life may be viewed as having equal or even
greater importance than absolute survival.8
Only recently has HRQOL been a specific focus of study in
patients with PAH. Preliminary evaluations using non-disease-
specific questionnaires have identified profound impairment
in the HRQOL of patients with PAH, comparable to that seen
in other life-threatening and even fatal disease states.9e13
Indeed, Shafazand et al. found that despite current therapy,
patients with PAH reported a willingness to accept a 29% risk
of certain death in exchange for a possible cure.9 Efforts at
improving HRQOL in patients with PAH will require validated
and potentially disease-specific assessment tools, to identify
factors whose change might positively impact HRQOL.14
The Minnesota Living with Heart Failure (MLHF) question-
naire was designed and validated for the assessment of
HRQOL in patients with heart failure, and is widely applied in
studies of patients treated for left-sided heart dysfunction.15
As both the symptoms and outcome of patients with PAH are
predominantly determined by the consequences of right
heart failure, Cenedese et al. recently validated a simple
modification of the MLHF to allow HRQOL assessment specif-
ically in patients with pulmonary hypertension.16 They vali-
dated this pulmonary hypertension-specific version of the
MLHF in 26 patients with PAH, and additionally demonstrated
its reliability and responsiveness to change. We have now ap-
plied this disease-specific tool to assess HRQOL in a larger
population of patients with PAH than previously studied.Methods
Study design and patients
We performed a cross-sectional assessment of HRQOL using
a disease-specific HRQOL tool. Newly referred and estab-
lished patients were asked to complete HRQOL question-
naires between July 2004 and December 2005. Only patients
with World Health Organization (WHO) Group 1 disease (PAH)
as defined by the 2003 World Symposium on PH were
included.17,18 Patients were evaluated according to standard
guidelines, including confirmation of a mean pulmonary ar-
tery pressure >25 mmHg at rest or >30 mmHg with exertion
and exclusion of significant left heart or respiratory dis-
ease.19,20 Patients completed HRQOL questionnaires without
prompting during outpatient appointments. Physicians and
nurses providing care were unaware of patient responses.
Patient demographics, symptoms, and medications on
the day of HRQOL evaluations were obtained by chart
review. Cardiac catheterization results within 12 months
were recorded.
Health-related quality of life measurements
We administered a modification of the MLHF disease-
specific HRQOL survey validated for assessment of patients
with pulmonary hypertension (MLHF-PH).16 In place of
‘‘your heart failure,’’ patients are asked to report the
degree to which ‘‘your pulmonary hypertension’’ affects
various aspects of daily life (see Appendix I). The MLHF-
PH has 21 questions and is scored from zero to 105, with
higher scores indicating worse HRQOL. The survey yields
a total score, providing an overall assessment of satisfac-
tion with life as influenced by health. The MLHF-PH also
specifically evaluates physical and emotional HRQOL sepa-
rately as physical and emotional domain scores. A patient
without PH, or who does not attribute any symptoms to
it, should have a MLHF-PH score of zero.
For comparison to disease-specific HRQOL evaluations,
we simultaneously administered the Medical Outcomes
Survey 36 Item Short Form health survey (SF-36).21 This val-
idated non-disease-specific questionnaire is widely used to
assess HRQOL in multiple diseased populations. The SF-36
has 36 questions yielding scaled scores in 8 physical/mental
health domains and overall physical and mental component
summary scores. In contrast to the MLHF-PH, higher scores
on the SF-36 indicate better HRQOL.
Statistical analysis
HRQOL scores of the MLHF-PH and SF-36 were calculated
according to published instructions, including imputation for
missing data.21,22 To facilitate comparison across domains,
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of 10 based on the normal US population.21 Normative values
for the MLHF and MLHF-PH do not exist as these surveys are
specifically designed for patients with CHF and PH, respec-
tively. A patient whose HRQOL is unaffected by CHF (for
the MLHF) or PH (for the MLHF-PH) would have a score of
zero.
Data were entered into Access 5.1 (Microsoft Corpora-
tion) and analysis performed using SAS 9.1 (SAS Institute;
Cary, NC). Differences were assessed using an independent
t-test for binary predictors, ANOVA for categorical
predictors, and correlation coefficients for continuous
measures. Comparisons between patient groups were
limited to the MLHF-PH physical, emotional and total
scores, and the SF-36 physical and mental component
summary scores. Significant associations were defined as
p 0.05 without adjustment for multiple comparisons in
this hypothesis-generating evaluation.23 Prior to modeling,
we examined the distributions of the three MLHF-PH scales
and the two SF-36 scales, each of which was near normal.
The ShapiroeWilk statistic, which ranges from 0 to 1, where
values near 1 indicate near normality, ranged from 0.93
through 0.99 for the SF-36 and MLHF-PH scales in our sam-
ple, indicating near normality of the outcome measures and
the use of parametric statistical tests.24 While our analytic
methods utilized parametric tests, additional confirmation
was performed with secondary nonparametric tests (Spear-
man correlation and Wilcoxon rank sum as appropriate) to
account for any deviations of the assumed normality as
well as the sampling process.
This study was approved by the Institutional Review
Board of the University of Pennsylvania.
Results
Patient characteristics
HRQOL was assessed in 93 outpatients with PAH (WHO
Group 1 disease). The population was 80% female with an
average age of 50 years, ranging from 18e81. More than
half of the patients were married and 16 percent reported
living alone. Approximately one-half had idiopathic PAH
(IPAH), and nearly all had NYHA/WHO functional Class II or
III symptoms as assessed by their physicians. Thirteen
percent of patients completed HRQOL surveys at their
initial evaluation in a PH specialty clinic, whereas the
remainder of assessments were made in patients followed
for up to one, three and five years in 15, 27 and 32 percent
of patients, respectively. The rest (13 percent) had
received care specifically for PAH for more than five years.
Table 1 shows other physical/social characteristics of the
population.
Pulmonary hypertension disease-specific
HRQOL scores
Assessments of each physical, emotional and overall HRQOL
using the pulmonary hypertension-specific MLHF-PH question-
naire revealed severe impairments (Fig. 1). The total MLHF-PH
score indicated significant problems in HRQOL (p< 0.001).
Both the mean physical and emotional dimension scores ofthe MLHF-PH also were elevated (p< 0.001 each), indicating
patients’ assessment of the effects of pulmonary
hypertension on satisfaction with life and ability to function
as desired.
Factors associated with HRQOL scores
on the MLHF-PH
Demographics
To facilitate comparisons, significant differences in HRQOL
scores according to patient-specific factors are summarized
in Table 2; full results are presented in Appendix II. As
compared with other forms of PAH, patients with disease
associated with scleroderma had significantly worse
HRQOL. Physical dimension and total summary scores on
the MLHF-PH for patients with scleroderma were more
severely impaired than those of patients with idiopathic
PAH. Patients with NYHA/WHO functional Class II symptoms
had better physical, emotional and total summary scores
than patients with NYHA/WHO Class III symptoms. Living
alone was also associated with worse emotional dimension
scores on the MLHF-PH. Neither gender, race, nor marital
status was associated with better or worse HRQOL scores.
Symptoms
Certain symptoms were associated with worsened HRQOL.
Abdominal complaints (e.g., bloating and ‘‘fullness’’) and
symptoms of fatigue or weakness were associated with signif-
icantlyworse physical dimension scores. Abdominal complaints
were additionally associatedwith worse total summary scores.
Symptoms of weakness or fatigue occurred more frequently
with more severely impaired emotional and total summary
scores. Chest pain was associated with worse emotional scores
but not physical and total summary scores. Other commonly
reported symptoms including leg swelling (35% of patients) and
lightheadedness (26%) were not associated with MLHF-PH
scores. Common side effects of epoprostenol therapy
(diarrhea, jaw pain) were not related to HRQOL scores.
Therapies
Therapies were also assessed. Patients treated with
continuously infused epoprostenol reported significantly
worse effects of PAH on HRQOL. As compared with other
patients, physical dimension, emotional dimension, and
total summary MLHF-PH scores were worse. No differences
in HRQOL scores were found according to the use or non-use
of either calcium channel antagonists or bosentan. Small
numbers treated with sildenafil precluded evaluation. Pa-
tients receiving warfarin reported significantly worse phys-
ical and total summary scores. No such associations were
found according to the use of oxygen, digoxin or diuretics.
Hemodynamic values
Although increases in themean right atrial pressure correlated
with worsened physical dimension scores (correlationZ 0.29,
pZ 0.05) and total summary scores (correlationZ 0.36,
pZ 0.01), no other relationship to hemodynamic values was
identified. Neither mean PA pressures, cardiac output/index,
nor pulmonary vascular resistance values was correlated with
any of the three MLHF-PH quality of life measurement scales
(Fig. 2).
Table 1 Population characteristics
Physical characteristics (n, % except as indicated) Social characteristics (n,%)
Patients, n 93 Marital status
Age, years (mean SD) 50 13 Single 24 (26)
Female 74 (80) Married 54 (58)
Caucasian 65 (69) Separated 3 (3)
African American 14 (15) Divorced 6 (6)
Hispanic 3 (3) Widowed 4 (6)
Asian 1 (1) Unknown 2 (2)
Other 12 (12) Lives alone 15 (16)
PAH diagnosis Substance abuse
Idiopathic (PAH) 44 (47) Prior alcohol 7 (8)
Familial 3 (3) Current alcohol 6 (6)
Systemic sclerosis 16 (17) Prior smoking 30 (32)
Other CVD 3 (3) Current smoking 5 (15)
Anorectic agent use 3 (3) Treatments (n,%)
Liver disease 6 (6) Epoprostenol 26 (28)
HIV 2 (2) Bosentan 46 949)
Congenital heart disease/shunt lesions 14 (15) Calcium channel blocker 44 (47)
PVOD 2 (2) Sildenafil 3 (3)
NYHA CLASS I 4 (4) Warfarin 46 (49)
NYHA CLASS II 45 (48) Digoxin 31 (33)
NYHA CLASS III 42 (45) Diuretics 53 (57)
NYHA CLASS IV 1 (1) Oxygen, continuous 24 (26)
Hemodynamics (mean SD)
Mean RA pressure (mmHg) 9.1 6.1
Mean PA pressure (mmHg) 45 14
Cardiac output (liters/min) 4.9 1.9
Cardiac index (liters/min/m2) 2.7 0.9
PVR (dynes sec cm5) 689 494
Symptoms (# of patients/% reporting)
Lower extremity swelling 33 (35)
Abdominal fullness 14 (15)
Pre-syncope/lightheadedness 24 (26)
Chest pain 19 (20)
Fatigue/weakness 47 (51)
Diarrhea 8 (9)
Jaw pain 9 (10)
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lated with physical dimension scores (correlationZ0.35,
pZ 0.001) and total summary scores (correlationZ0.27,
p< 0.05). Emotional dimension scores were not associated
with oxyhemoglobin saturation.Comparison with HRQOL scores on
non-disease-specific surveys
Simultaneous HRQOL evaluations were made using the non-
disease-specific SF-36 in order to compare the utility of
pulmonary hypertension-specific and non-disease-specific
HRQOL assessments. Like the MLHF-PH, the SF-36 identified
severe impairment in each physical and mental HRQOL
(p< 0.001 for the comparison of each with US population
normative scores). Deficiencies were additionally found in
each of the eight HRQOL domains assessed by the SF-36,
except bodily pain (Fig. 3).Table 2 summarizes those factors identified as being
associated with worse HRQOL by either the disease-specific
(MLHF-PH) or non-disease-specific (SF-36) surveys. Each
survey similarly identified associations between several
patient-specific factors and physical aspects of HRQOL (as
indicated by the physical dimension and component scores
of the MLHF-PH and SF-36, respectively). In the evaluation
of physical aspects of HRQOL, discrepancies between the
two modes of evaluation occurred in the associations iden-
tified with living alone, the presence of pre-syncope or the
use of oxygen (each associated with SF-36 physical compo-
nent scores but not the MLHF-PH) and the use of warfarin or
bosentan (each associated with MLHF-PH but not SF-36
scores). Associations between various factors and emo-
tional HRQOL were more often identified by the disease-
specific MLHF-PH than by the SF-36. Use of the MLHF-PH
total score for overall HRQOL did not identify additional as-
sociations not seen in either the emotional or physical com-
ponent scores.
Figure 1 Pulmonary hypertension-specific HRQOL scores.
Shown are mean SD scores for each the emotional and phys-
ical components of the MLHF-PH, as well as the total score
evaluating overall HRQOL. Higher scores indicate worse
HRQOL. Each mean score indicates significant impairment in
HRQOL (p< 0.001 for each, as compared to the normal score
of zero in each scale of the MLHF-PH).
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Remarkable progress in understanding the pathogenesis of
PAH has led to a rapid growth in therapeutic options.
Multiple classes of drugs are now available, as well as
options for their route of administration. These advances
have led to improvements in important endpoints, including
hemodynamics, exercise capacity and survival. Expanding
therapeutic options might allow consideration of additional
factors when deciding a patient’s treatment, including the
effect of therapeutic choices on HRQOL. Such consideration
is particularly important considering the significant impair-
ments in both exercise capacity and survival that persistTable 2 Comparison of HRQOL scores assessed by disease-spec
SF-36-physical
component
MLHF-PH phys
dimension
Living alone X
Abdominal fullness X X
Pre-syncope X
Chest pain
Fatigue/weakness X X
Warfarin X
IV epoprostenol X
Bosentan
Oxygen X
Scleroderma vs. other
Group I PAH diagnosis
X X
Scleroderma vs. IPAH X X
NYHA/WHO Functional
Class II vs. Class III
X X
Indicated are significant (p< 0.05) association between the patient fa
Note that unlike the MLHF-PH, there is no corresponding overall (tota
full score details in each assessment.despite current therapies. Currently, however, little is
known regarding the determinants of HRQOL in PAH,
including the best means of assessment.
A few recent studies have begun to specifically assess
HRQOL in patients with PAH. Evaluations using non-PAH
specific questionnaires have consistently demonstrated
impaired HRQOL.9e13,16 Two groups have recently estab-
lished the validity of PH-specific assessment tools. McKenna
and colleagues developed a novel questionnaire (the CAM-
PHOR) and Cenedese et al. modified a widely used and
well-established tool specifically for use in patients with
PH (the MLHF-PH).13,16,25 Both the CAMPHOR and MLHF-PH
yield highly reproducible and valid measures of HRQOL in
patients with PAH. The MLHF-PH was additionally shown
to be a responsive measure with sensitivity to changes in
HRQOL with treatment. In a multivariate analysis including
common invasive and non-invasive measures, patients’
MLHF-PH scores were also shown to be predictive of subse-
quent clinical worsening, including death. Chua et al.
compared the performance of the SF-36, MLHF and the
Australian QOL questionnaires and found the SF-36 and
MLHF to be sensitive to measures of functional and exercise
capacity.11
We, therefore, applied the disease-specific MLHF-PH to
a larger population of patients with PAH. Severely impaired
HRQOL was identified, even among patients using medica-
tions known to improve exercise capacity and survival. We
identified demographic, symptom, examination, and treat-
ment factors associated with better or worse HRQOL.
Significantly impaired HRQOL was also identified by the
non-disease-specific SF-36. No clear advantage of either
method was seen for evaluating individual patients.
Although the MLHF-PH did more often identify associations
with emotional domains of HRQOL, the relative utility of
these questionnaires as research tools requires prospective
studies in additional populations and with attention to
change over time and prediction of outcomes. Accordingly,
Cenedese et al. have demonstrated the MLHF-PH to beific and non-disease-specific questionnaires
ical SF-36-mental
component
MLHF-PH
emotional
dimension
MLHF-PH total
summary score
X
X
X
X X X
X
X X
X
X
X X
ctor and worse HRQOL, which was identified by the HRQOL scale.
l) score generated by the SF-36 questionnaire. See Appendix II for
Figure 2 Relationship between MLHF-PH scores and hemodynamic values. Lack of correlation between most hemodynamic
values and the scores on each physical domain and emotional domain and total MLHF-PH scores. An association was only identified
between the right atrial (RA) pressure and the physical domain and total MLHF-PH scores (with correlation coefficient and corre-
sponding p values as indicated). Nonparametric analysis resulted in similar values (rZ 0.31, pZ 0.033 for the association with
physical domain score and rZ 0.37, pZ 0.012 for the total MLHF-PH score). None of the other hemodynamic values had significant
correlations with any of the MLHF-PH scores. PA, pulmonary artery; PVR, pulmonary vascular resistance.
1436 M. Zlupko et al.predictive of outcomes, as noted above. Chua et al.
compared the ability of each the MLHF, SF-36 and the
Australian Quality of Life questionnaires to detect change
in HRQOL over time, and found the MLHF and SF-36 to be
most responsive, in addition to correlating well with other
baseline measures of functional status.11
Despite the availability of only a few studies thus far
focusing specifically on HRQOL in PAH, quality of life has
been consistently impaired regardless of whether assess-
ments are made before or after therapy, or the ques-
tionnaire used. Study of HRQOL is important in PAH forseveral reasons. Patients may perceive the effects of
impaired hemodynamic values and six-minute walk dis-
tances differently. These differences may be influenced
by their pre-morbid status, comorbidities, life-styles and
expectations. Further, although improved by current
therapies, survival remains significantly reduced for
most patients with PAH. It is, therefore, appropriate
that factors influencing a patient’s satisfaction with
overall HRQOL be addressed when evaluating care. In-
deed, recent studies have shown that hemodynamic
values no longer reliably predict survival in patients
Figure 3 Non-disease-specific HRQOL scores. Shown are the mean SD scores on the SF-36. Both physical and emotional com-
ponent scores (left) and individual domain scores (right) are shown. Each mean score is significantly different from the normal
US population score (p< 0. 001), with the exception of bodily pain. Higher scores on the SF-36 indicate better HRQOL.
Disease-specific quality of life in pulmonary hypertension 1437with PAH. The identification of previously unrecognized
predictors of survival in patients with PAH (e.g., race and
socioeconomic status) underscores the importance of
evaluating new means of assessing outcomes.26 Indeed
in other populations, impaired HRQOL is associated
with markedly increased mortality independent of other
medical issues.27,28
The present study has several limitations. Retrospec-
tive collection of patient data may result in misclassifi-
cation bias thereby influencing the associations
identified. Furthermore, in responding to questions on
the MLHF, it is unknown whether patients readily differ-
entiate between symptoms caused by PH and those
resulting from comorbidities. The cross-sectional design
does not allow evaluation of changes in HRQOL in
response to individual treatments. As we are unable to
control for differences between patients that influenced
the choice of therapies, it is important to recognize that
no firm conclusions can be drawn regarding their relative
effects on HRQOL. Such comparisons will require pro-
spective studies. The modification made to the MLHF to
foster assessment of HRQOL in patients who identify their
health problem as ‘‘pulmonary hypertension’’ as opposed
to ‘‘heart failure’’ may limit the ability to compare our
results with other studies using the original, non-modified
MLHF to assess patients with other causes of heart
failure. In addition, it is unknown how discussions
between physicians and patients about PAH, or the extentto which patients learn about PAH via available resources
(e.g., the internet) impacts HRQOL; study of such poten-
tial influences on HRQOL will require additional assess-
ment tools. Additional study is also required to assess
whether the MLHF-PH accurately predicts outcome in this
population.
In conclusion, we have applied a recently validated
pulmonary hypertension-specific HRQOL assessment tool to
a larger population of patients with PAH than previously
studied by this method. Scores on the MLHF-PH were
severely impaired, underscoring the need for future
prospective studies aimed at identifying factors which
determine and the interventions that might improve HRQOL
in patients with PAH. While further study is required to
assess whether changes in factors associated with worse
HRQOL in the current study can result in improved
outcomes, the availability of disease-specific and validated
tools, such as the MLHF-PH, should enable continued
progress toward this goal.Conflicts of interest
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